title: Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
abstract: BACKGROUND
  Long-term outcome data of central precocious puberty (CPP) girls treated with gonadotropin-releasing hormone analogue (GnRHa) are conflicting.
  
  
  OBJECTIVE
  To assess long-term outcome of girls with idiopathic CPP (iCPP) treated with GnRHa.
  
  
  METHODS
  We compared adult height (AH), body mass index (BMI) and time of menarche in GnRHa-treated (n = 47) and untreated (n = 11) girls with iCPP.
  
  
  RESULTS
  There were no differences in age, bone age, height, weight and BMI z-scores, predicted adult height (PAH) at the time of diagnosis and target height between the two groups. Mean (SD) age of GnRHa-treated girls was 8.5 (1.0) years at the start of treatment. Mean (SD) AH of the treated group was greater [158.6 (5.2) vs. 154.8 (5.6) cm], p < 0.05. AH gain over pre-treatment PAH in the treated group was 4.7 cm. BMI z-score of treated girls was 1.26 (0.95) before the treatment initiated and returned to normal [0.16 (1.0)] at the time of AH reached. Menstruation occurred at 0.9 (0.5) years following GnRHa discontinuation with regular pattern.
  
  
  CONCLUSIONS
  Long-term GnRHa therapy has a modest beneficial effect on adult height gain in girls with iCPP. No detrimental effects on increasing BMI and hypothalamic-pituitary-gonadal axis reactivation are demonstrated.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
authors.forename: Preamrudee
authors.initials: P
authors.lastname: Poomthavorn
authors.forename: Ratchadaporn
authors.initials: R
authors.lastname: Suphasit
authors.forename: Pat
authors.initials: P
authors.lastname: Mahachoklertwattana
mesh_terms: D000293:Adolescent; D041923:Adolescent Development / Q000187:drug effects; D001827:Body Height / Q000187:drug effects*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D002648:Child; D002657:Child Development / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006130:Growth Disorders / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008572:Menarche / Q000187:drug effects*; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D007987:Gonadotropin-Releasing Hormone